Bruno Cardoso Lab

Myeloid Malignancies Lab
Bruno Caetano Cardoso

Understanding what drives leukemia growth and thriving is crucial to fight these diseases. Despite the recent advances in understanding the pathophysiology of several myeloid malignancies, treatment options remain highly limited and are not curative for most of these patients.

Our main goal is to uncover disease biology and use such discoveries to design novel, therapeutic regiments that maximize treatment efficacy while minimize the severe side effects associated with the standard chemotherapy.

In line with this, two independent research avenues are in place in the Lab to tackle these aggressive malignancies:

  1. Cross-talk between Leukemic cells and bone marrow microenvironment
  2. Linking the circadian molecular clock to myeloid leukemogenesis

Keywords: Myeloid Malignancies; Microenvironment; Targeted therapies; Epigenetic therapy

Research Team:

Bruno Martins, Msc (researcher)

Selected references:

  1. Bruno A. Cardoso. The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression. Adv Exp Med Biol. 2020;1219:259-293. doi: 10.1007/978-3-030-34025-4_14.
  2. Bruno A. Cardoso, Teresa L. Ramos, Hélio Belo, Filipe Vilas-Boas, Carla Real and António M. Almeida. Vorinostat synergizes with Antioxidant therapy to target Myeloproliferative Neoplasms. Exp Hematol. 2019 Apr; 72:60-71.e11. doi: 10.1016/j.exphem.2019.02.002. Epub 2019 Feb 13.
  3. Cardoso BA, Belo H, Barata JT, Almeida AM. The Bone Marrow-Mediated protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signaling Pathways. PLoS One. 2015 Dec 1; 10 (12): e0143897.